Navigation Links
New target identified for preventing bone destruction in diseases such as arthritis and cancer
Date:12/4/2013

The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts. This coordinated activity is essential for maintaining healthy bone. However, excessive osteoclast activity leads to bone destruction in skeletal diseases such as osteoporosis, rheumatoid arthritis and cancer metastases in bone. A family of signaling enzymes known as phosphatidylinositol 3-kinases (PI3Ks) control diverse cell functions but, up until now, little was known about the function of specific PI3K isoforms in osteoclasts.

A paper published in the December 6 issue of The Journal of Biological Chemistry announces the characterization of a new potent and selective PI3Kdelta inhibitor, GS-9820. The discovery was made by members of Western University's Bone and Joint Initiative with collaborators from Nihon University, the University of Calgary and Gilead Sciences, Inc.

Graduate student Ryan Shugg, working under the supervision of Stephen Sims, PhD, and Jeff Dixon, PhD, of Western's Department of Physiology and Pharmacology, used a panel of isoform-selective inhibitors and found that one isoform in particular, PI3Kdelta, regulates osteoclast shape and resorptive activity.

Sims says, "These findings suggest that selective inhibition of PI3K isoforms offers a new approach for the treatment of inflammatory bone diseases and skeletal metastases."

The studies were carried out by an interdisciplinary team, which included undergraduate student Ashley Thomson, visiting professor Natsuko Tanabe, research scientist Alexey Pereverzev, investigator Frank Jirik at the McCaig Institute for Bone and Joint Health (University of Calgary), along with researchers Adam Kashishian, Bart Steiner, Kamal Puri, and Brian Lannutti from Gilead Sciences.

"Collaboration among researchers at Gilead Sciences, Western, Calgary and Nihon Universities was critical for accessing and testing this novel inhibitor" says Sims. "Such partnerships are essential for translating progress in fundamental cell biology into therapeutic advances."


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert  

Related biology news :

1. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
2. Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
3. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
4. Nanobubbles plus chemotherapy equals single-cell cancer targeting
5. Researchers identify Achilles heel of dengue virus, target for future vaccines
6. Scientists identify FLT3 gene as a valid therapeutic target in acute myeloid leukemia
7. Genetically modified corn affects its symbiotic relationship with non-target soil organisms
8. Unique adaptations to a symbiotic lifestyle reveal novel targets for aphid insecticides
9. Yeast cell reaction to Zoloft suggests alternative cause, drug target for depression
10. Key proteins newly discovered form and function may provide novel cancer treatment target
11. Scientists discover new inflammatory target
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New target identified for preventing bone destruction in diseases such as arthritis and cancer
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... YORK , April 4, 2017   EyeLock ... today announced that the United States Patent and Trademark ... patent broadly covers the linking of an iris image ... same transaction) and represents the company,s 45 th ... latest patent is very timely given the multi-modal biometric ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... ... September 22, 2017 , ... Brain State ... via Kickstarter. The proceeds will be used to fund production of the company’s ... original Kickstarter goal by nearly 1,000%. , The B2v2 is the world’s first ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... colleague Dr. Justin Zalewsky in offering LANAP® and LAPIP™ laser treatments. Drs. Hoge ... True Regeneration™ to patients, a minimally invasive and less painful option that produces ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... ulcers is now being assessed in clinical trials in the United States. (clinicaltrials.gov ... to your nurse or physician or find your nearest participating clinic here ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of ... 27th. His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo ... West and discuss how probiotics have shown impressive data in areas outside the gut ...
Breaking Biology Technology: